SAN DIEGO--(BUSINESS WIRE)--Optimer Pharmaceuticals, Inc. (NASDAQ:OPTR) today announced financial results for the third quarter and nine months ended September 30, 2007. Optimer reported a net loss allocable to common stockholders for the third quarter of 2007 of $6.5 million or, $0.28 per common share, as compared to a net loss of $2.2 million, or $0.86 per common share, for the comparable quarter in 2006. The increase of $4.2 million was due primarily to funds spent for the advancement of Optimer’s OPT-80 and Prulifloxacin clinical trials.
